HomeTrialNCT05206513
🔬NCT05206513Phase 3ACTIVE NOT RECRUITING

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Study Summary

The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment86 participants
Primary Completion
Lead SponsorNeurocrine Biosciences
Data Retrieved2026-04-11 04:22:17.614688+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.